All In Biotech

Drug Trial Radar · NCT05116202

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Feb 2, 2022

Primary completion

Sep 22, 2023

Study completion May 28, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV melanoma (Cohort 2). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and modify the participant population.

Conditions

  • Melanoma

Interventions

  • NivolumabDrug

    Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.

  • IpilimumabDrug

    Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.

  • RO7247669 2100 mgDrug

    RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.

  • AtezolizumabDrug

    Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.

  • TiragolumabDrug

    Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.

  • RO7247669 600 mgDrug

    RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Response Rate (pRR) for Cohort 1 as Determined by Independent Pathologic ReviewTime frame: Time of surgery (scheduled at Week 7)
  2. Objective Response Rate (ORR) for Cohort 2 as Determined by the InvestigatorTime frame: From randomization up to approximately 3.6 months

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • The Angeles Clinic and Research Institute - W LA Office

    Los Angeles, California

  • Moffitt Cancer Center

    Tampa, Florida

  • MD Anderson Cancer Center

    Houston, Texas

  • Melanoma Institute Australia

    North Sydney, New South Wales, Australia

  • Hopital de la Timone

    Marseille, France

  • APHP - Hospital Saint Louis

    Paris, France

  • Institut Universitaire du Cancer de Toulouse-Oncopole

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Azienda Ospedaliera Universitaria Senese

    Siena, Abruzzo, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, Campania, Italy

  • Istituto Europeo Di Oncologia

    Milan, Lombardy, Italy

  • Ospedale S.Maria della Misericordia

    Perugia, Umbria, Italy

  • Hospital Universitario Vall d Hebron

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.